Lilly's scored its cluster headache nod for Emgality. Will it shake up the CGRP race?

Eli Lilly's Emgality didn't just hit the next-gen migraine market in third place behind Amgen and Novartis' Aimovig and Teva's Ajovy. It's been trailing its CGRP rivals in early sales results, too. But now Emgality is alone in boasting a cluster headache approval.